PIONYR IMMUNOTHERAPEUTICS

Pionyr Immunotherapeutics is a clinical stage company developing cancer immunotherapies that target the tumor microenvironment to enhance the body's antitumor immunity... Pionyr's Myeloid Tuning™ programs are designed to enhance the immune system's anti-tumor response by specifically altering the cellular infiltrate of the tumor microenvironment. Pionyr's clinical programs, PY314 and PY159, targeting TREM2 and TREM1 respectively, are designed to selectively deplete and, in some cases, reprogram certain tumor-associated macrophages responsible for immunosuppression. PY314 and PY159 have demonstrated safety alone and in combination with pembrolizumab in Phase 1a/b trials. Pionyr's third program, PY265 (anti-MARCO) is IND-ready.

Also known as: Pionyr Immunotherapeutics, Inc.